Glaucoma Treatment in 2026

1. The 2026 Treatment Landscape at a Glance
The 2026 AAO Preferred Practice Pattern for Primary Open-Angle Glaucoma (POAG) and the EGS 6th Edition Guidelines converge on a central principle: individualized care based on disease severity, patient adherence, and quality-of-life impact. The era of simply escalating eye drops has ended. Today’s ophthalmologist draws from four tiers:
First-line options now include both topical prostaglandin analogues AND selective laser trabeculoplasty (SLT), supported by six-year extension data from the landmark LiGHT trial and a 2022 Cochrane review showing lower disease progression with laser vs. drops alone.
Sustained-release implants (Durysta, iDose TR) eliminate daily drop burden for 6-36 months per administration, directly addressing the adherence crisis.
MIGS procedures offer a middle ground between medication and traditional surgery for patients with mild-to-moderate disease — with the caveat that they are not appropriate for advanced glaucoma requiring substantial pressure reduction (EGS 2026).
Neuroprotective agents in late-stage trials target retinal ganglion cell survival directly, independent of pressure control — representing a potential paradigm shift.
2. Sustained-Release Implants: Solving the Adherence Crisis
Studies consistently demonstrate that 30-50% of glaucoma patients do not adhere to their daily drop regimen within the first year (AAO 2026 PPP). The consequence is uncontrolled intraocular pressure (IOP) and progressive, irreversible optic nerve damage. Two FDA-approved implants now directly address this problem.
2.1 Durysta (bimatoprost implant, AbbVie)
Durysta is a dissolvable pellet containing bimatoprost (a prostaglandin analogue) injected into the anterior chamber of the eye during an in-office procedure. It delivers medication steadily over approximately 3-6 months. A critical limitation: the FDA has approved it for only one implant per eye per lifetime due to concerns about corneal endothelial cell loss with repeat dosing (AAO 2026). Medicare Part B covers Durysta as a physician-administered drug; patients pay 20% coinsurance after meeting the annual Part B deductible ($283 in 2026). The cash price ranges from approximately $2,000-$4,000 per administration, though actual patient cost varies significantly by insurance plan.
2.2 iDose TR (travoprost implant, Glaukos)
iDose TR is a titanium implant placed in the trabecular meshwork that continuously elutes travoprost for up to 36 months. Unlike Durysta, iDose TR is designed for replacement once depleted and does not carry the same single-use limitation. The cash price is approximately $14,573 per implant (Drugs.com, 2026). For commercially insured patients, the manufacturer’s savings program may reduce out-of-pocket cost to as little as $0. However, this program is NOT available to Medicare, Medicaid, or VA patients. Medicare coverage for iDose TR requires confirmation through the patient’s specific Part B or Medicare Advantage plan and may involve prior authorization.
3. Laser Therapy: SLT Now Firmly First-Line
The AAO 2026 PPP more strongly endorses Selective Laser Trabeculoplasty (SLT) as a first-line therapy, equal to topical medications. Six-year LiGHT trial extension data show patients receiving SLT first experienced less disease progression and required fewer additional surgeries compared to those starting on drops alone. Economic analyses further confirm SLT’s cost-effectiveness under real-world adherence conditions.
The procedure is straightforward: performed in-office, takes approximately 5-10 minutes per eye, uses laser energy to stimulate the eye’s natural drainage system (trabecular meshwork), and typically produces IOP reductions of 20-30%. A newer variant, Direct Selective Laser Trabeculoplasty (DSLT), removes the need for a contact lens but has not yet demonstrated noninferiority to conventional SLT.
MicroPulse laser therapy continues gaining adoption as a repeatable, non-incisional alternative that delivers energy in microsecond pulses, minimizing collateral tissue damage. Meta-analysis data suggest similar IOP lowering to continuous-wave cyclophotocoagulation but with fewer severe complications (AAO 2026). Both SLT and MicroPulse are covered by Medicare Part B and most commercial plans when medically necessary.
4. MIGS: Appropriate Patients, Realistic Expectations
Minimally Invasive Glaucoma Surgery (MIGS) devices — including the Kahook Dual Blade, OMNI Surgical System, Hydrus Microstent, and gonioscopy-assisted transluminal trabeculotomy (GATT) — have become standard tools for mild to moderate POAG, often combined with cataract surgery. The EGS 2026 guidelines offer an important caution: MIGS typically produces modest IOP reduction and should not be used as a default when the clinical situation demands more substantial pressure lowering.
For advanced disease, the AAO 2026 PPP reaffirms trabeculectomy as the benchmark for achieving low target IOP, citing five-year data from the Treatment of Advanced Glaucoma Study (TAGS) showing primary trabeculectomy achieved lower IOP and less progression than primary medical therapy in advanced disease with similar safety profiles. Tube shunt surgery (e.g., Baerveldt, Ahmed) remains a proven alternative with comparable long-term outcomes.
5. The Neuroprotection Pipeline: Beyond Pressure Control
The traditional glaucoma model treats IOP as the sole modifiable variable. 2026 marks the year this paradigm begins to crack. Neuroprotective agents — compounds designed to prevent retinal ganglion cell death independent of pressure — are now in Phase II and III trials.
Notable candidates include BL1107 (Bausch + Lomb), an alpha-2 adrenergic agonist that has demonstrated statistically significant visual field mean deviation improvement versus timolol in early studies, with larger Phase II results expected later in 2026. QLS-111 (Qlaris Bio), an ATP-sensitive potassium channel modulator that lowers IOP via a novel mechanism (reducing episcleral venous pressure), showed an additional 3.2-3.6 mmHg reduction when added to latanoprost in Phase II trials. NCX 470 (Nicox), a nitric oxide-donating bimatoprost, demonstrated superior IOP reduction vs. latanoprost in two Phase III trials and has NDA submissions underway in the U.S. and China. None of these are yet FDA-approved for neuroprotection claims, but they represent the treatment horizon your ophthalmologist is watching.
6. Insurance Coverage and Out-of-Pocket Costs: What U.S. Patients Need to Know
The cost barrier is real and varies dramatically by insurance type:
Treatment Medicare Part B Medicare Part D Commercial Insurance
Prostaglandin eye drops (generic latanoprost) Not covered (self-administered) Covered; typical copay $5-15/month Covered; copay varies by plan
Durysta implant Covered (20% coinsurance after $283 deductible) Not applicable (physician-administered) Typically covered; prior auth may apply
iDose TR implant Coverage varies; prior auth likely Not applicable Covered; manufacturer savings program available
SLT laser Covered (20% coinsurance) Not applicable Typically covered with specialist copay
MIGS + cataract surgery Covered as medically necessary Not applicable Covered; combined procedures may affect cost-sharing

Medicare also covers a glaucoma screening once every 12 months for high-risk beneficiaries: African Americans aged 50+, Hispanic Americans aged 65+, and individuals with diabetes or a family history of glaucoma (Medicare.gov). For those with financial hardship, the manufacturer patient assistance programs (myAbbVie Assist for Durysta; iDose TR Patient Savings Program for commercially insured) and Medicare Extra Help (income-based subsidy) can substantially reduce out-of-pocket costs.
7. Patient Action Checklist: Before Your Next Eye Appointment
1. Confirm your diagnosis: primary open-angle, angle-closure, or normal-tension glaucoma. Treatment pathways differ significantly.
2. Ask your ophthalmologist about SLT as a first-line option if you are newly diagnosed or struggling with drop adherence.
3. If you miss drops more than twice a week, ask whether sustained-release implants (Durysta or iDose TR) are appropriate for your disease stage.
4. Request a written cost estimate from both your doctor’s billing office and your insurer BEFORE scheduling any procedure.
5. If you are on Medicare, confirm whether your procedure falls under Part B or Part D to avoid surprise bills.
6. For advanced glaucoma, ask whether trabeculectomy or tube shunt surgery may provide better long-term pressure control than MIGS.
7. Get a baseline visual field test and OCT scan before starting any new treatment so you can objectively track progression.
8. If you are of African American or Hispanic background, verify your Medicare glaucoma screening eligibility (annual screening covered).
8. Frequently Asked Questions
Q: Is SLT better than eye drops for newly diagnosed glaucoma?
A: The LiGHT trial’s six-year data support SLT as at least equivalent — and in some measures superior — to topical medication for first-line POAG treatment, with lower disease progression rates and reduced need for additional surgery. The AAO 2026 PPP now endorses both as first-line options. The best choice depends on your specific IOP targets, adherence capability, and insurance coverage.
Q: Does Medicare cover the iDose TR or Durysta implants?
A: Medicare Part B covers Durysta for its FDA-approved indication (single implant per eye per lifetime). iDose TR coverage under Medicare varies by plan — neither traditional Medicare nor Medicare Advantage has issued a uniform national coverage determination as of mid-2026. Prior authorization is commonly required. The manufacturer’s $0 copay savings program is only available to commercially insured patients, not Medicare or Medicaid beneficiaries.
Q: Can glaucoma damage be reversed with the new treatments?
A: No. As of 2026, no treatment can reverse existing optic nerve damage or restore lost vision. All approved therapies — including implants, MIGS, and lasers — aim to slow or halt further progression by lowering IOP. Neuroprotective agents in clinical trials (BL1107, QLS-111) are exploring whether retinal ganglion cell survival can be enhanced, but they do not claim to reverse existing damage.
Q: How often do I need follow-up after an implant or MIGS procedure?
A: Typical monitoring schedules: SLT follow-up at 4-6 weeks post-procedure, then 3-6 month intervals. After Durysta or iDose TR, ophthalmologists usually schedule checks at 1 day, 1 week, 1 month, and then every 3-6 months depending on IOP stability. MIGS patients are typically seen at 1 day, 1 week, 1 month, 3 months, and then every 6-12 months. These are general guidelines — your specialist will tailor the schedule to your disease severity.
Q: What are the warning signs that my glaucoma treatment is failing?
A: Any of the following warrant prompt re-evaluation: progressive visual field loss on perimetry testing despite treatment, optic nerve thinning visible on OCT despite treatment, IOP consistently above your target range, new difficulty with night driving or peripheral awareness, or increasing frequency of headaches or eye discomfort. Do not wait for your next scheduled appointment if you notice these changes.
9. Sources
1. American Academy of Ophthalmology, Preferred Practice Pattern: Primary Open-Angle Glaucoma, 2026 Update
2. European Glaucoma Society, Terminology and Guidelines for Glaucoma, 6th Edition, 2026
3. LiGHT Trial 6-Year Extension Data — Gazzard G, et al. Lancet. 2023; (referenced in AAO 2026 PPP)
4. Treatment of Advanced Glaucoma Study (TAGS) 5-Year Results — King AJ, et al. Ophthalmology. 2022
5. Glaucoma Research Foundation, Glaucoma Facts & Stats, 2026. glaucoma.org/facts-stats
6. Review of Ophthalmology, The 2026 Glaucoma Pipeline, January 2026
7. Ophthalmology Times, Glaucoma Innovation: Eight Themes to Watch in 2026, January 2026
8. Medicare.gov, Glaucoma Screening Coverage. Medicare Part B Benefits
9. LegalClarity.org, Medicare Coverage for Bimatoprost/Durysta, 2026
10. Drugs.com, iDose TR Price Guide, 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for professional diagnosis, treatment, or consultation with a licensed ophthalmologist. Treatment decisions should be made in consultation with your eye care provider based on your individual medical history, disease severity, and insurance coverage. Do not delay seeking medical attention or disregard professional advice because of information presented here. If you experience sudden vision changes, eye pain, or symptoms of acute angle-closure glaucoma (severe eye pain, nausea, blurred vision, halos around lights), seek emergency medical care immediately.